The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

<p>Abstract</p> <p>Objectives</p> <p>Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative efficacy of dasatinib an...

Full description

Bibliographic Details
Main Authors: Mealing Stuart, Barcena Leticia, Hawkins Neil, Clark James, Eaton Victoria, Hirji Ishan, Davis Catherine
Format: Article
Language:English
Published: BMC 2013-02-01
Series:Experimental Hematology & Oncology
Subjects:
Dasatinib
CML
Chronic myeloid leukaemia
Network meta-analysis
Systematic review
Relative efficacy
Online Access:http://www.ehoonline.org/content/2/1/5

Internet

http://www.ehoonline.org/content/2/1/5

Similar Items